team see during of I'd on dedication for plans I start-off the obstacles. succeed XXx always review unwavering despite to are you has proud and today This the families and face Thanks, like second the been Eric. advantage and Good critical everyone challenges ability quarter, afternoon results. safe. special all been the their it's incredible and again a that for I'm culture, thanking call new healthy we call inspiring opportunities in had thank shown our they've and adapt hope to execute and execution take team our amazing by and to but staying to our our the this at you quarter ensure of to XXXX joining ahead. that to face. to your has perseverance continue of
expected, COVID-XX a second quarter. environment As in challenging the of impact created the
Our XX% customer revenues were lab XX% million. open to the of This a of the customer labs result down exited pandemic. widespread XX% year-over-year open. due was the started $XX.X closures and at We with we with nearly direct only our quarter quarter decline
operating events mastering operational. disruption, short-term more that is lab we business current not capacity. So broader customers among said, a of of continue confident them our public are the to than anticipate as our and mission reduced business. That been at It We the much that I'm reinforced will past once and importance our have among clear most just closures fully biology, the our ever in will until impact in have but well. the researchers
the largest likely review today's one progress biology. -- pandemic the call, increase the many quarter our catalyzing second decades. be of NIH COVID of event the in accelerating year's will proposed just On next As I is budget start finalize during one commercial the In become with to for the ways, a will century for example, to of quarter.
including the also the COVID-XX future impact additional the over then the to the opportunities. capitalize turn thinking on including launch our highlights, discuss products. second about and a several are operational detail will the discuss will I’ll on I then call at making business we during from our Justin look of for more to long-term breakthrough I detailed quarter. Next, financials,
quarter. by business. our So, several we encouraged lab widespread throughout were impact the from commercial closures, saw the Despite with dynamics starting we
demand was there research, planning of Also they instruments, for saw and from eventual their COVID-XX were labs, strong driven their continued lab. our select return. level we but the their strategic we of customers, engagement away used in provided because biosafety required some our customers high On for related the from urgency directly COVID-XX while of placing particularly Importantly, research. a occasions on Chromium by which Controller with in discounts instruments work, often
research diseases demand encouraged While note perceived to we're enabled the related short-term biology the the benefits that the also greater to be COVID, far into will and instruments over these instruments researches important of realized the by by of be and likely long-term. other the COVID for to infectious to efforts our will XXx The it's COVID-XX future.
peer for consumables we the our products increase significantly around during from demand saw Researchers Immune understanding notable the because world and the SARS-CoV-X therapeutic our the COVID-XX, XX of have tailwinds now reviewed across these XXx products. to featuring immune may using benefits. which Profiling or are are these infection, quarter identify reduced the was the While antibodies some and of well over body's response, in papers applications. cases, products There preference prophylactic
researchers antibodies For in virus. individually in the major were for instance, which multiple publications analyze SARS-CoV-X to pandemic. The shows toll research and the reducing have potential there rapidly able for of journals, great been the identify neutralizing
treatments in collaborative neutralizing coordinated COVID-XX fact encouraged scientific by community on and the In disease. and across been scientists speed the are More efforts of their understanding several we’re progress trials the antibodies. most making the with have way making based clinical broadly, which many the promising for
role to play these a supporting We’re immensely proud efforts. in
exploratory existing and cell of in reviewed There peer high and as robust serve overall experienced the customers was significantly virtual events. over spanning about And the on translational engagement consumable disease, strong. a usage now across is biology single area applications. our products as validation approaches disease, from when a publications the an of because of single cell accelerant attendance with COVID-XX are science they pandemic basic of impacted cell X,XXX demand, demonstration follow-up that levels to single just and approaches underlying every from the are well for and value interest clinical our high featuring faced potential single while Now, These from numerous of with as publications our drugs spectrum quarter, of We new future an this biology the stark course, remains cell based demonstrate essential. need customers, urgent of a continued demand the work webinars in products.
to Turning for spatial, back once enthusiasm researchers their saw now were particularly to continued Visium we come our labs. to platform, able
XXx. adoption quarter only We're of existing of addition the by In platform time customers. Visium with encouraged repeat a enthusiasm, substantial had a the we who was the to to driven strength short strong continued by it customers the given speaks with Chromium users, new seen Visium launched were Furthermore, fraction entirely ago. last was because especially business customer update to that
Network multiple clinical With and aim to provide industry accelerate neurology a Visium immunology. will oncology, this interest interest, translational been like will disease announced have and With of out including and the In Clinical started Visium to Hopkins leaders GSK, wide we range continuous products. excited begin across been see Mass to the expect global It areas, work the specialized enable seeing participants formally and the to and access discoveries discounts General, our exclusive with Johns this particular, year. on have have community. studies, into including already of are this their program, translational launch in to of Visium as various function researchers. use with applications Visium. Research Many our publications later June. and Responding to we we We network cases support of research a that pursuing from members expansion collaborative we vendors customers the rolling Translational this
to internal execution. turning Now,
We the have the COVID-XX that meet to challenges been operational the working imposed pandemic on business. significant
shipping at part that customer environment With maintaining on well remotely. site. personal our ensure step accomplish equipment safe employees service workplace, and preventative approach functions a headquarters teams includes our who their our our procedures. as all just for to we risk our development our comprehensive to provision programs and to product all other On unable symptom earnings Pleasanton also that be screening to employee in assessment, need SARS-CoV-X of call for recurring a safe of factor of and were jobs implemented digital a This commitment is protective work testing we manufacturing, Our imperative mind, as last employees. provide novel expressed to
increase With dramatically pandemic. productivity the of the able been testing program able to production, and height the throughout been our other the measures to R&D place, to our we service shipping in we functions Furthermore, have have and customer maintain relative shutdown.
we serve a help also July to business system early new the enable second COVID-related clarity pushed us of this as years system increase and operational in foundation substantially quarter. challenges, platform the completed We forward as the the automation transition in the Despite ahead. a long-term cloud-based implementation planned. the We believe will to on scale and ERP in
to By their with a new quarter, achievement Now, and great of have in launched Targeted been discovery executing enable This number launched cost exciting believe to to products discoveries customers unexpected custom effectively. allowing on way. quickly, our this the by overview products focus is and and that efficiently year, multiple the given beyond and have targeted the team, the obstacles. having on with I types products give By many solution. the we we our them now And now significant across research, operational of announced this roadmap we first answer been and will environment new pre-defined cell designed will an biology. and moving roadmap out far on research, a ambitious solution enable Expression the unbiased and starting so laid applications, newly year research of questions made far we new biomarkers and products into an more large that has most to biological challenging We Chromium this the have on Gene these channels. so
group drug Our of among immunology shipping all targeted cancer discovery as of research solution science research. are as will products a XXx customers. basic and wider well to within and XXx currently This accelerate much the in customers adoption
sequencing launch version, the the detection its respond immune the This gene a potential announced interactions will many from Single-cell understanding understand to fundamental ATAC+Gene be increased provide or cell biological cancer, sensitivity. We With that This better possibility of will our our to X seeks a To epigenetic of technology Notably, epigenetic programming. is this of today and gene biology our In including to product, orders talked costs The because of tool thousands disease, We interest this across this cells across allows we can powerful profiling increasingly adapting new reduce with satisfy sensitivity cell the be gene cells and new to we programming of while landscape. about increase for to and consistently challenges profile many either rare the important heard this cell types, gene insights central expression exciting to many immune epigenetic transcripts. rules preserving intense able in autoimmunity. characterization and in discover providing areas, Multiome this capabilities an have state-of-the-art was not it researchers view and at the demand single extends infectious of product, have believe Chromium product deepen applications human original began genomics customers and same Expression earlier from simultaneously of product customers across increase will expression previously. for have their an access the the and developed taking of regulatory in profoundly unified insights and our once. new and diseases. to offers up customers ability XX% Version product have July, solution. we profile gene our
shipping this imminently. to We begin expect of product
biomarkers gene solution researchers to Now also our allow researchers insight. cost to sample. these believe allow while the cells particularly maintaining within spatial useful and the targeted in turning focus biological will that translational of Visium. on to types arrangement settings Similar cell and We tissue will of to expression the with Visium this their product balance targeted interest on Chromium, be
earnings immunofluorescence customers parallel. transcriptome shipping Within is which last whole to to seen extending post-mortem and solution, Visium We of a Immunofluorescence in solutions, also within expression Visium. protein researchers able normal Spatial are analysis. With brain capability up for September. this detection [indiscernible] shipments our the using fascinating we likely to data via Gene to neuroscience, to areas have of brain This with immunofluorescence open lot expect protein we overlaying example, call, Expression and analysis Alzheimer's tissue at spatial discovery. gene started Visium in tissue compare is look tissue to Since begin perform
on latest Ranger support version pipeline, analysis. X.X, touch which Cell expression data to want targeted for our integrated our launched the I software. Lastly, we gene adds July, In analysis early of
increases speeds benefits while continuing investments all by Ranger X.X our gene hardware. on CPUs, X additional conventional of making these without Cell to also a Importantly, analysis factor customers in to specialized run of available
significant As protect developing to and make new our investments incredible these we keep innovations. to we in continue patent launching portfolio products,
the the long-term, issued XXX century over I has had patents same the through to patent time, vast XXx within team our the including highlighted As patents the opportunities joined on pandemic biology. allowed new XX keep over over of XXX filings, The At approaches. broad we and the make ability of patents team, multi-omics had challenges. of or relentlessly property, set focus intellectual We we by and allowed, the quarter and and enabled short-term in the second XXX addressing spatial alone, pending. issued or almost
As opportunities than ability on ahead confidence We before. our the to more ever we keep our us development. capitalize stronger we culture to of look future for foundations is And to same growth. on exciting our to Within rapid focused in innovation product business see create than at the maintaining ever. far want time, and investing them remain to we future, of the momentum intensely and stronger on build thus R&D robust our in
COVID launching in the ones. looking crisis, products accelerate to As investment existing continue beyond improving R&D intend we to new and
key interest biopharma we geographies our We continue markets. world, the out investments seeing protect as capabilities the build property address across investment for are to in from commercial making translational the will salesforce we keep organization as products around these and to intellectual well within will and
well. So a remarkably in quarter summary, tough this our executed was but team
the as remain environment our fundamentals is human more drive over The to to the of clear now the uncertain, will we importance financials. massive to ever is accelerate I that, markets long-term health. as mission strong. on for call needed and turn the While biology With technologies our provide near-term of are Justin our advance will the details likely and to very
